A Phase 2 Randomized Placebo Controlled Double Blind Proof-of-Concept Study of the Efficacy and Safety of PF-02545920 in Subjects with Huntington's Disease
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to compare the safety, tolerability and effectiveness of two doses of PF-02545920 to placebo on improving voluntary movement and overall symptoms in subjects with Huntington's disease.
Description
The purpose of this study is to assess the efficacy pf 26-week oral daily dosing with PF-02545920 on motor function in subjects with Huntington's disease.
Details
| Condition | Huntington's disease |
|---|---|
| Age | 30years - 65years |
| Clinical Study Identifier | TX4420 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.